The combination of DPP-4 inhibitors and SGLT2 inhibitors resulted in higher direct medical costs but also increased total QALYs by 0.24. The incremental cost-effectiveness ratio for that pathway ...

SGLT2 inhibitors did not reduce the risk for adverse liver outcomes more than DPP-4 inhibitors in patients with type 2 diabetes and metabolic dysfunction–associated steatotic liver disease.

Alogliptin (NESINA), a dipeptidyl peptidase IV (DPP-4) inhibitor, was approved by the FDA on January 25, 2013 to improve blood sugar control in adults with type 2 diabetes. This drug had been ...

Bristol-Myers Squibb and AstraZeneca have filed their new type 2 diabetes compound saxagliptin, which they hope will be able to provide some competition to Merck & Co’s big-selling dipeptidyl ...

The EMPRISE real-world evidence study involves nearly 382,000 people with type 2 diabetes from 12 countries providing a comprehensive clinical picture of empagliflozin in treating people with type ...

Once upon a time, Merck was looking to candidate omarigliptin—a once-weekly DPP-4 diabetes med—to build up declining sales of its Januvia/Janumet franchise. But no more. Late last week, the ...

Merck & Co has scored its first regulatory approval for omarigliptin, a DPP-4 inhibitor for diabetes that need only be dosed once a week. Japan’s Pharmaceuticals and Medical Devices Agency (PMDA) has ...

As if last week's Jardiance news wasn't enough to worry makers of DPP-4 diabetes drugs, the FDA has now issued a warning that the class of meds might cause "severe and disabling" joint pain.

Researchers noted fDPP-4 discriminated clinical activity from remission with areas under the curve of 0.8 (95% CI, 0.68-0.93) and 0.76 (95% CI, 0.58-0.94) in patients with UC and CD, respectively.

The DPP-4 enzyme is expressed in many tissues, but perhaps it’s best known for its role in glucose and insulin metabolism. By degrading GLP-1, DPP-4 can reduce insulin secretion.

The rate difference was −5.78 per 1,000 person-years for GLP-1 RA users versus DPP-4i users (hazard ratio, 0.90; 95 percent confidence interval, 0.82 to 0.98).